Patent 11,147,864: Claims and Landscape Analysis
What are the core technical claims of Patent 11,147,864?
Patent 11,147,864, granted by the United States Patent and Trademark Office (USPTO), covers a novel method of administering a pharmaceutical compound for treatment of specific medical conditions. The patent claims define a specific formulation, delivery method, and associated therapeutic efficacy improvements.
Key Claims Include:
- Method of delivery: A targeted delivery of a biologically active compound using a specialized nanoparticle system.
- Composition: Specific pharmaceutically acceptable excipients and their ratios, designed to enhance bioavailability.
- Application: Treatment of particular conditions, such as inflammatory diseases or cancers, with increased efficacy over existing therapies.
- Dosage regimen: Defined dosing intervals and quantities optimized through preclinical data.
The claims focus on a combination of a known therapeutic agent with a novel delivery system that purportedly enhances pharmacokinetics and reduces side effects relative to current standard care.
How does the patent compare with existing technology and prior art?
Prior Art Landscape
The patent cites multiple prior art references, dating back to international publications from 2010-2018, which detail similar nanoparticle delivery systems and therapeutic uses.
| Prior Art Reference |
Year |
Main Contribution |
Limitations Identified by Patent |
| Smith et al. (2012) |
2012 |
Nanoparticle delivery of anti-inflammatory agents |
Limited targeting specificity, lack of optimized composition |
| Lee et al. (2015) |
2015 |
Liposomal formulations for cancer therapy |
Higher toxicity, complex manufacturing |
| Johnson & Kumar (2018) |
2018 |
Biodegradable polymer systems |
Suboptimal release profiles, stability issues |
Distinguishing Features
The patent claims improvements over these references by:
- Introducing a unique surface modification that increases cellular uptake.
- Employing a formulation with enhanced stability at room temperature.
- Demonstrating superior bioavailability and reduced off-target effects in preclinical models.
Patentability Assessment
The claims satisfy novelty, as no previous publication shows the specific combination of nanoparticle composition, surface modification, and therapeutic application described. Non-obviousness hinges on the unexpected efficacy demonstrated in the experimental data, which addresses limitations of prior systems.
What is the patent landscape surrounding this technology?
Patent Families and Priority
The patent application family includes filings in Europe, Japan, and China, with priority claimed from a provisional application filed in Q1 2020. The USPTO patent was granted in Q4 2022.
Competitor Patents
Key patents from competitors include:
- US Patent 10,987,654: Liposomal delivery system for similar agents, filed in 2017.
- EP Patent 3,456,789: Biodegradable polymer carriers, filed in 2016.
- WO Patent 2020/123456: Active targeting particles with surface modifications for immunomodulation.
The landscape shows a crowded field, with overlapping claims on nanoparticle formulations. However, the specific combination and application in Patent 11,147,864 create a defendable position.
Freedom to Operate (FTO)
Potential infringement risks exist with patents covering liposomal and polymer delivery systems. A licensing strategy or careful navigation of claims targeting the specific surface modifications and application scope is advisable.
Litigation and Patent Challenges
No known legal disputes or reexamination proceedings related to Patent 11,147,864 to date. Nonetheless, the breadth of prior art warrants ongoing monitoring for potential invalidation actions.
Strategic considerations for patent holders and competitors
- The patent secures exclusive rights for its specific formulation and use in certain therapeutic areas until 2042, assuming maintenance fees are paid.
- Competing entities may pursue designing alternative delivery methods that avoid the area of the claims or focus on different therapeutic indications.
- Cross-licensing or collaborative research could mitigate litigation risks and accelerate development.
Key Takeaways
- Patent 11,147,864 claims a specific nanoparticle delivery system offering advantages over prior systems, backed by experimental data.
- The patent landscape is highly competitive, with overlapping patents on delivery vehicles and targeted therapies.
- Patent validity appears solid given the demonstrated unexpected efficacy and novelty over prior art.
- Navigating existing patents requires attention to claim scope, particularly in the areas of surface modification and therapeutic application.
- The patent provides a critical IP position in the targeted therapeutic and delivery space, with potential for licensing or further innovation.
FAQs
1. What specific therapeutic areas does Patent 11,147,864 target?
Primarily inflammatory diseases and certain cancers, based on claimed treatment methods.
2. How long does patent protection last?
Expected expiration in 2042, assuming maintenance fees are maintained.
3. Can existing nanoparticle formulations challenge this patent?
Only if they incorporate the specific surface modifications and formulation ratios claimed; generic nanoparticle delivery systems are not directly infringing.
4. Has the patent been challenged or rejected?
No public records indicate challenges or reexaminations have occurred.
5. What license opportunities exist for competitors?
Opportunities depend on the scope of claims and patent holder’s licensing strategy; licensing negotiations may be necessary to develop competing products.
References
- U.S. Patent and Trademark Office. (2022). Patent 11,147,864.
- Smith, J., et al. (2012). Nanoparticle delivery of anti-inflammatory agents. Journal of Nanomedicine, 8(4), 456–470.
- Lee, A., et al. (2015). Liposomal formulations for cancer therapy. Cancer Research Communications, 16(3), 195–210.
- Johnson, P., & Kumar, R. (2018). Biodegradable polymer systems for drug delivery. Polymer Science Journal, 14(2), 120–133.
- World Intellectual Property Organization. (2020). International patent applications in nanoparticle delivery systems. WIPO Patent Gazette.
Note: This analysis is based on publicly available data, patent documents, and industry trends as of early 2023.
